[{"id":"0ff63797-5bfd-4773-893e-1563164054ca","acronym":"OTT-19-06","url":"https://clinicaltrials.gov/study/NCT04676516","created_at":"2021-01-19T20:45:48.594Z","updated_at":"2025-02-25T13:19:48.698Z","phase":"Phase 2","brief_title":"A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer","source_id_and_acronym":"NCT04676516 - OTT-19-06","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" HER-2 • ER • TP53 • PGR • CD8 • CD4 • FOXP1","pipe":" | ","alterations":" HER-2 negative • TP53 wild-type • PGR positive","tags":["HER-2 • ER • TP53 • PGR • CD8 • CD4 • FOXP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • TP53 wild-type • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemrametostat (GSK3326595)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/15/2022","study_completion_date":" 08/15/2022","last_update_posted":"2022-10-25"}]